Advertisement

GRYT Health and BMS launch COVID-19 Advocacy Exchange

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GRYT Health and Bristol Myers Squibb Co. developed the COVID Advocacy Exchange, a virtual platform to connect patient advocacy organizations, patients, policy makers, healthcare practitioners, and industry in the exchange of information.

The COVID Advocacy Exchange will invite close to 100 global and local advocacy organizations, spanning disease states, to virtually meet and support patients with serious diseases while navigating the current COVID-19 pandemic. The virtual platform will provide access to data and information, as well as the opportunity to participate in weekly live, interactive sessions to foster discussion and collaboration.

The virtual platform will provide advocacy organizations and patients with access to materials and information offering support across the following disease areas: oncology, cardiovascular, immunology & fibrosis, hematology and multiple sclerosis. Participants will have access to materials from Bristol Myers Squibb, other advocacy organizations and third-party experts, including curated best practices, white papers, peer-reviewed articles and multimedia content addressing the unique advocacy challenges associated with the COVID-19 pandemic for advocates and patients. Resources to address digital fundraising and other issues exacerbated by the pandemic will also be available.

Exhibitor information and the first weekly live, interactive session will be available here, launching the week of May 18. To register for free access to the platform and the series, visit www.covidadvocacyexchange.com.

Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement